Anti-HIV agents. Merck integrase inhibitor.
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D009930:Organic Chemicals / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D063065:Organophosphonates / Q000008:administration & dosage / Q000627:therapeutic use; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D000068698:Tenofovir
D019380:Anti-HIV Agents; D019428:HIV Integrase Inhibitors; D009930:Organic Chemicals; D063065:Organophosphonates; D011760:Pyrrolidinones; D019259:Lamivudine; D000068898:Raltegravir Potassium; D000068698:Tenofovir; D000225:Adenine